Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations
Status:
Withdrawn
Trial end date:
2020-12-01
Target enrollment:
Participant gender:
Summary
This phase II trial studies intermittent dosing of BRAF inhibitor LGX818 (encorafenib) and
MEK inhibitor MEK 162 (binimetinib) in treating patients with melanoma that has spread to
other parts of the body (metastatic) and have a BRAF V600 mutation. LGX818 and MEK162 may
stop the growth of tumor cells by blocking different enzymes needed for cell growth. Giving
LGX818 and MEK162 with breaks between each course (intermittently) may help delay the time
when tumors become resistant to the drugs.